The global cancer supportive care drugs market size is projected to reach USD 22.9 billion by 2026, as per a new report by Grand View Research, Inc. It is expected to progress at a CAGR of 1.0% over the forecast period. Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment.
Key
side effects caused by cancer treatment include anemia, neutropenia, nausea and
vomiting, pain, and bone metastasis. Rise in the number of people suffering
from the effects of anti-cancer therapies will drive the market, globally. The
higher efficacy of supportive care drugs, such as colony stimulating factors
(G-CSFs), opioid analgesics, erythropoietins, and antiemetic drugs, among
others is anticipated to drive growth of the global cancer supportive care
drugs market. High efficiency of these drugs in controlling the adverse effects
of cancer and its treatment is projected to drive the demand in near future.
G-CSFs
and ESAs therapeutic classes are witnessing a fundamental shift from biologics
to biosimilars. The market for cancer pain, chemotherapy induced nausea and
vomiting, and cancer induced bone diseases will grow significantly during the
forecast period, due to new product launches and high unmet needs. The cancer
pain market is estimated to witness a shift from opioids to non-opioids
therapies. The shift will be backed by patent loss, high mortality, addiction,
and major safety issues associated with narcotic agents.
Full Research Report On Cancer Supportive Care Drugs Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/cancer-supportive-care-drugs-market
Further key
findings from the report suggest:
- Some of the
key market players are Amgen, Merck, Novartis, Johnson & Johnson,
Roche, Helsinn Healthcare, Heron Pharma, Tesaro, and Purdue Pharma. Amgen
led the global cancer supportive care market in 2018, capturing over 30%
market share
- By
therapeutic class, the global ESAs market for CIA was valued at USD 1,838
million in 2018 and is expected to decline with a CAGR of 6.0% over the
forecast period. The biologics segment is anticipated to lose its market
share due to patent expiration of major brands such as Epogen
- North America
led the cancer supportive care drugs market in 2018 and is expected to
maintain its position during the forecast period
- Asia Pacific
is expected to witness lucrative growth over the forecast period, owing to
improvements in healthcare infrastructure and increasing government
initiatives
- Late stage
pipeline products include non-opioids such as Tanezumab and HTX-011. Newer
immunotherapies directed against PD-1 ligands and PD-L1 proteins have
shown to be more effective with a superior safety profile
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/cancer-supportive-care-drugs-market/request/rs1
Grand View Research has
segmented the global cancer supportive care drugs market based on therapeutic
class and region:
Cancer Supportive
Care Drugs Therapeutic Class Outlook (Revenue, USD Million, 2015 - 2026)
- G-CSFs (Granulocyte-colony Stimulating Factors)
- ESAs (Erythropoiesis Stimulating Agents)
- Anti-emetics
- Bisphosphonates
- Opioids
- NSAIDs
Cancer Supportive
Care Drugs Regional Outlook (Revenue, USD Million, 2015 - 2026)
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- France
- Spain
- Asia Pacific
- India
- China
- Japan
- Thailand
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment